Cyteir Therapeutics Inc

NASDAQ CYT

Data sourced from

and

Download Data

Cyteir Therapeutics Inc Cash to Debt Ratio for the Trailing 12 Months (TTM) ending September 30, 2023

Cyteir Therapeutics Inc Cash to Debt Ratio is NA for the Trailing 12 Months (TTM) ending September 30, 2023. The cash to debt ratio assesses a company's ability to cover its total debt obligations with its available cash. It is calculated by dividing cash by total debt. This ratio indicates the company's liquidity and its capacity to meet its debt obligations using its cash reserves. A higher cash to debt ratio suggests a stronger ability to cover debts with cash resources.

NASDAQ: CYT

Cyteir Therapeutics Inc

CEO	Mr. Joseph S. Zakrzewski
IPO Date	June 18, 2021
Location	United States
Headquarters	128 Spring Street, Lexington, MA, United States, 02421
Employees	46
Sector	Healthcare
Industry	Biotechnology

Description

Cyteir Therapeutics, Inc., a clinical-stage biotechnology company, develops and commercializes the oncology therapeutics. Its lead product CYT-0851, an oral investigational drug that inhibits monocarboxylate transporters that is in Phase I/II clinical trial for monotherapy in solid tumors and hematologic malignancies, as well as for combination therapy in solid tumors and hematologic malignancies. Cyteir Therapeutics, Inc. was incorporated in 2012 and is headquartered in Lexington, Massachusetts.

Key trends